Sales Meeting – Western Region – January 14 2008         Focus: Taxane Related Products
Why pursue Taxane based products?“This places screams engineering – engineering is your strong point” - Doug Johnson, Allos:
Why pursue Taxane based products?Taxane based products require large amounts of engineering•  Combination of aqueous & lip...
Why pursue Taxane based products?Docetaxel to expire 2010Vinorelbine – off-patent since 2003
Lipid-Soluble API FormulationSN-38   NeoPharm, Inc.   Enzon Pharmaceuticals, IncTaxanes   RTI, International   Cell Therap...
Small to Mid-Pharma with Ongoing Clinical TrialsDocetaxel    RTI, International        Novacea    Cell Therapeutics, Inc. ...
Why pursue Taxane based products?Taxane based products require large amounts of engineering•  Combination of aqueous & lip...
How widespread are Taxane based products How widespread areTaxane based products?Docetaxel   Docetaxel-     809 on-going s...
Recent NewsDocetaxel   02 Jan 2008 NEOPHARM, Inc. today announced that it has filed an investigational new drug   applicat...
“Promote it and they will come” HCM to Paperazzi                 Current HCM Client to closest CMO Distance 700 ft        ...
Upcoming SlideShare
Loading in …5
×

Al gunduz sales intro to 2008

416 views

Published on

Sales goals for Al Gunduz - 2008

Published in: Technology, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
416
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Al gunduz sales intro to 2008

  1. 1. Sales Meeting – Western Region – January 14 2008 Focus: Taxane Related Products
  2. 2. Why pursue Taxane based products?“This places screams engineering – engineering is your strong point” - Doug Johnson, Allos:
  3. 3. Why pursue Taxane based products?Taxane based products require large amounts of engineering• Combination of aqueous & lipid phases• Homogenization• Microfluidization• Possible cytotoxic lyophilization?
  4. 4. Why pursue Taxane based products?Docetaxel to expire 2010Vinorelbine – off-patent since 2003
  5. 5. Lipid-Soluble API FormulationSN-38 NeoPharm, Inc. Enzon Pharmaceuticals, IncTaxanes RTI, International Cell Therapeutics, Inc. Azaya Therapeutics
  6. 6. Small to Mid-Pharma with Ongoing Clinical TrialsDocetaxel RTI, International Novacea Cell Therapeutics, Inc. Zeneus Pharma Azaya Therapeutics Genta Incorporated MethylGene Poniard Pharmaceuticals Ascenta Therapeutics Seattle Genetics, Inc. Cell Genesys GPC Biotech Titan Pharmaceuticals Proacta, Incorporated Cytogen Corporation Keryx Biopharmaceuticals Tibotec Therapeutics Infinity Pharmaceuticals, Inc. ONYX Pharmaceuticals Cytokinetics, Inc. AmpliMed Corporation Semafore Pharmaceuticals Inc.CPT-11 EMD Serono, Inc. Celgene Corporation Wellstat Therapeutics YM BioSciences Adnexus Dynavax Technologies Corporation ImClone Systems
  7. 7. Why pursue Taxane based products?Taxane based products require large amounts of engineering• Combination of aqueous & lipid phases• Homogenization• Microfluidization• Possible cytotoxic lyophilization?
  8. 8. How widespread are Taxane based products How widespread areTaxane based products?Docetaxel Docetaxel- 809 on-going studies Vinorelbine- 160 on-going studies CPT-11- 210 on-going studies SN-38- 13 on-going studies
  9. 9. Recent NewsDocetaxel 02 Jan 2008 NEOPHARM, Inc. today announced that it has filed an investigational new drug application with the FDA for a novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere(R) (docetaxel), for the treatment of patients with locally advanced or metastatic solid tumor after failure of prior chemotherapy WAUKEGAN, IL, USA | January 2, 2008 | NEOPHARM, Inc. (NASDAQ:NEOL) today announced that it has filed an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for a novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere(R) (docetaxel), for the treatment of patients with locally advanced or metastatic solid tumor after failure of prior chemotherapy.
  10. 10. “Promote it and they will come” HCM to Paperazzi Current HCM Client to closest CMO Distance 700 ft Distance 500 ft

×